Nespo Европска Унија - Фински - EMA (European Medicines Agency)

nespo

dompé biotec s.p.a. - darbepoetiini alfa - kidney failure, chronic; anemia; cancer - antianemiset valmisteet - krooniseen munuaisten vajaatoimintaan (crf) liittyvän oireisen anemian hoito aikuisilla ja pediatrisilla potilailla. oireisen anemian hoito solunsalpaajia saavilla aikuisilla syöpäpotilailla, joilla on ei-myeloidinen syöpä.

Physioneal 35 Glucose Clear-Flex 13.6 mg/ml peritoneaalidialyysineste Финска - Фински - Fimea (Suomen lääkevirasto)

physioneal 35 glucose clear-flex 13.6 mg/ml peritoneaalidialyysineste

baxter oy - calcium chloride dihydrate, glucose monohydrate, magnesium chloride hexahydrate, sodium bicarbonate, sodium chloride, sodium lactate - peritoneaalidialyysineste - 13.6 mg/ml - isotoniset liuokset

Physioneal 35 Glucose Clear-Flex 22.7 mg/ml peritoneaalidialyysineste Финска - Фински - Fimea (Suomen lääkevirasto)

physioneal 35 glucose clear-flex 22.7 mg/ml peritoneaalidialyysineste

baxter oy - calcium chloride dihydrate, glucose monohydrate, magnesium chloride hexahydrate, sodium bicarbonate, sodium chloride, sodium lactate - peritoneaalidialyysineste - 22.7 mg/ml - hypertoniset liuokset

Physioneal 35 Glucose Clear-Flex 38.6 mg/ml peritoneaalidialyysineste Финска - Фински - Fimea (Suomen lääkevirasto)

physioneal 35 glucose clear-flex 38.6 mg/ml peritoneaalidialyysineste

baxter oy - calcium chloride dihydrate, glucose monohydrate, magnesium chloride hexahydrate, sodium bicarbonate, sodium chloride, sodium lactate - peritoneaalidialyysineste - 38.6 mg/ml - hypertoniset liuokset

Physioneal 40 Glucose Clear-Flex 13.6 mg/ml peritoneaalidialyysineste Финска - Фински - Fimea (Suomen lääkevirasto)

physioneal 40 glucose clear-flex 13.6 mg/ml peritoneaalidialyysineste

baxter oy - calcium chloride dihydrate, glucose monohydrate, magnesium chloride hexahydrate, sodium bicarbonate, sodium chloride, sodium lactate - peritoneaalidialyysineste - 13.6 mg/ml - isotoniset liuokset

Physioneal 40 Glucose Clear-Flex 22.7 mg/ml peritoneaalidialyysineste Финска - Фински - Fimea (Suomen lääkevirasto)

physioneal 40 glucose clear-flex 22.7 mg/ml peritoneaalidialyysineste

baxter oy - calcium chloride dihydrate, glucose monohydrate, magnesium chloride hexahydrate, sodium bicarbonate, sodium chloride, sodium lactate - peritoneaalidialyysineste - 22.7 mg/ml - hypertoniset liuokset

Physioneal 40 Glucose Clear-Flex 38.6 mg/ml peritoneaalidialyysineste Финска - Фински - Fimea (Suomen lääkevirasto)

physioneal 40 glucose clear-flex 38.6 mg/ml peritoneaalidialyysineste

baxter oy - calcium chloride dihydrate, glucose monohydrate, magnesium chloride hexahydrate, sodium bicarbonate, sodium chloride, sodium lactate - peritoneaalidialyysineste - 38.6 mg/ml - hypertoniset liuokset

Tezspire Европска Унија - Фински - EMA (European Medicines Agency)

tezspire

astrazeneca ab - tezepelumab - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Venclyxto Европска Унија - Фински - EMA (European Medicines Agency)

venclyxto

abbvie deutschland gmbh co. kg - venetoclax - leukemia, lymfosyyttinen, krooninen, b-solu - antineoplastiset aineet - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Pluvicto Европска Унија - Фински - EMA (European Medicines Agency)

pluvicto

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - eturauhasen kasvaimet, kastraatio-resistentin - terapeuttiset radiofarmaseuttiset valmisteet - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.